


1617

SEP 20 2002




**TRANSMITTAL LETTER**  
**(General - Patent Pending)**

Docket No.  
**P-188**

In Re Application Of: **Whitehead et al.**

Serial No.  
**09/938,009**



Filing Date  
**August 23, 2001**

Examiner  
**M. Bahar**

Group Art Unit  
**1617**

Title:

**METHODS FOR TREATMENT OF LUPUS ERYTHEMATOSUS**

**RECEIVED**  
**SEP 24 2002**  
**TECH CENTER 1600/2900**

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

Transmitted herewith is:

**Response to Restriction Requirement**

in the above identified application.

- ☒ No additional fee is required.
- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☐ The Commissioner is hereby authorized to charge and credit Deposit Account No. \_\_\_\_\_ as described below. A duplicate copy of this sheet is enclosed.
  - ☐ Charge the amount of \_\_\_\_\_
  - ☐ Credit any overpayment.
  - ☐ Charge any additional fee required.

*Signature*

**Robert W. Stevenson - 31064**  
**Cell Pathways, Inc.**  
**702 Electronic Drive**  
**Horsham, PA 19044**

Dated: **September 16, 2002**

CC:

I certify that this document and fee is being deposited  
**September 16, 2002** with the U.S. Postal Service as  
first class mail under 37 C.F.R. 1.8 and is addressed to the  
Commissioner of Patents and Trademarks, Washington,  
D.C. 20231.

*Signature of Person Mailing Correspondence*

**Tatiana Damico**

*Typed or Printed Name of Person Mailing Correspondence*

I hereby certify that this correspondence is being  
Mailed as First Class mail to the Commissioner of  
Patents and Trademarks, Washington, D.C. 20231

on September 16, 2002  
Date of Mailing

Tatiana Damico  
Name of applicant, assignee  
or Registered Representative

Tatiana Damico  
Signature

September 16, 2002  
Date of Signature

PATENT  
Case No. P-188

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )

Whitehead et al. )

Serial No.: 09/938,009 )

Filed: August 23, 2001 )

For: METHODS FOR TREATMENT OF )  
LUPUS ERYTHEMATOSUS )

Group Art Unit: 1617

Examiner: M. Bahar

RESPONSE TO RESTRICTION REQUIREMENT

Honorable Director of  
Patents and Trademarks  
Washington, D.C. 20231

Dear Sir:

Applicants' attorney thanks the Examiner for returning his phone message about the September 10, 2002 Restriction Requirement on her day off last Friday.

In our conversation, the undersigned noted that methods of group II represented a subset of group I because compounds presented in the claims in group II were PDE2 inhibitors as recited in the claims of group I. The Examiner indicated that if that was the case, groups I and II would be combined and examined together. If groups I and II are examined together, Applicants will agree to restrict groups III and IV simply for

RECEIVED  
SEP 24 2002  
TECH CENTER 1600/2600

#4  
9-26-02



convenience. If this case can proceed with an examination of claims 1-30 and 38 (i.e., groups I and II), Applicants will cancel the remaining claims at a later date after the Examiner indicates her agreement to this.

For a species, Applicants elect compound 38 (see p. 41 of the specification).

We look forward to an office action on the merits concerning Groups I and II.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Robert W. Stevenson", written over a horizontal line.

Robert W. Stevenson 31064  
Attorney for Applicants

September 16, 2002

CELL PATHWAYS, INC.  
702 Electronic Drive  
Horsham, PA 19044  
(215) 706-3800